LONDON, Nov 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab ... obesity drug 3:10 PM UTC Argentina's state-run oil company YPF will seek $2 billion in financing in the second quarter ...

Novo Nordisk's early data on Amycretin positions it as a potentially strong competitor to other oral obesity drugs, such as Lilly's orforglipron and Structure's GSBR-1290 ... several significant ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

Novo Nordisk (NVO) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...